RD, a 59-year-old male with newly diagnosed Burkitt's lymphoma, presents with high risk of tumor lysis syndrome based on his labs. The best treatment is rasburicase to rapidly reduce his high uric acid level and prevent renal failure, along with IV fluids and allopurinol for comprehensive management.
MM, a 62-year-old female with severe febrile neutropenia following chemotherapy, requires inpatient treatment with broad-spectrum IV antibiotics like meropenem and vancomycin due to her high risk status from low ANC, mucositis, and hypotension.
This document provides guidelines for prevention, risk stratification, and treatment of tumor lysis syndrome
3. CASE NO: 01
RD is a 59 year old male with newly diagnosed Burkitt’s
Lymphoma. Labs reveals WBC 12*109/ L , LDH = 810 IU/L ,
Potassium =5.7 mEq/L , SrCr= 2.1 mg/dl and uric acid 8.6
mg/dL .Vital signs and EKG are normal. Along with
allopurinol, which of the following is best to order first ?
a. 0.9% NS 1000ml * 1wide open
b. Rasburicase 0.2 mg /kg Iv *1
c. Sodium polystyrene Sulfonate
d. Consult for emergent renal dialysis
4. TUMOR LYSIS SYNDROME :
Oncologic emergency
Abrupt release of intracellular contents in high
quantity
Prophylaxis and treatment aimed at assisting
body to rid electrolyte excess
May be spontaneous or as a result of anti- cancer
therapy
Characterized by: elevated K+ ,PO4 and uric acid
with resultant decrease in calcium.
Howard SC et al.N Engl J Med;2011;364:1844-54
5. TUMOR LYSIS SNDROME- RISK FACTORS
Bulky, chemotherapy – sensitive disease.
Lymphoproliferative malignancy
Elevated lactate dehydrogenase (LDH)
WBC > 25*109 / L
Extensive bone marrow involvement
Baseline volume depletion /dehydration
Elevated baseline serum uric acid
Pre-existing renal dysfunction.
Howard SC et l, N Engl J Med 2011;364:1844-54
6. ADULT MALIGNANCIES STRATIFIED BY TLS RISK
DISEASE LOW-RISK INTERMEDIATE-
RISK
HIGH- RISK
NON-HODGKIN
LYMPHOMA
Indolent NHL
DLBCL with (a) non-
bulky disease (b) LDH
<2* ULN
Burkitt lymphoma with
normal LDH
DLBCL with (a) non-
bulky disease and (b)
LDH > 2 * ULN
Burkitt lymphoma
with (a) bulky disease
(b) elevated LDH
DLBCL with (a) bulky
disease and (b) LDH >
2 * ULN
ALL ----- WBC < 100 *109/L
and LDH normal
WBC > 100 *109/L
or LDH > 2* ULN
AML WBC <25*109/L
And LDH < 2* ULN
WBC 25 - 100 *109/L WBC >100 *109/L
CLL All other patients WBC > 50*109 /L
Treated with
fludarabine plus
rituximab or
bendamustine plus
rituximab
--------
7. PRINCIPLES OF TLS PROPHYLAXIS
All patients should be risk –stratified
Ideally, begin TLS prophylaxis 24-48 hours before
chemotherapy
Backbone of TLS prophylaxis:
Stop concomitant interacting pharmacotherapy
Saline –containing IVF to maintain urine output of
greater than equal to 100 ml /hr
Allopurinol 300-900 mg daily in divided doses.
Cairo MS et al Br J Haematol 2010; 149:578-86
8. PRINCIPLES OF TLS PROPHYLAXIS (CONT.)
Bicarbonate should not be added to IV
GOAL : maximize renal excretion of electrolytes
Uric acid nephropathy is most prevalent
nephrotoxin in TLS
Aggressive IV fluids and allopurinol dosing is
critical to maximize renal function
Rasburicase reserved for high–risk & pediatrics.
Cairo MS et al Br J Haematol 2010; 149:578-86
9. TLS PROPHYLAXIS IN LOW -RISK PATIENTS
o Monitor for development of TLS & complications.
Obtain labs every 24 hours
o No recommendation for hydration , oral route may
be employed
o No allopurinol or rasburicase.
o Clinical judgment and monitoring only
Cairo MS et al Br J Haematol 2010; 149:578-86
10. TLS PROPHYLAXIS IN
INTERMEDIATE RISK PATIENTS
o Monitor for development of TLS & complications.
Obtain labs every 8-12 hours
0.9% NS at rate of 2.5-3 litres /m2/day
Less may be used if patient fluid overloaded or oligouric at
baseline
Allopurinol 300-400 mg /m2/ day (adults) or 10-
20 mg /kg/day( children < 15 years ) PO or IV
Use loop diuretics as needed to administer
aggressive IV hydration
Cairo MS et al Br J Haematol 2010; 149:578-86
11. TLS PROPHYLAXIS IN HIGH -RISK
PATIENTS
o Monitor for development of TLS & complications.
Obtain labs every 6-8 hours
0.9% NS at rate of 2.5-3 liters /m2/day
Less may be used if patient fluid overloaded or oligouric at baseline
Allopurinol 300-400 mg /m2/ day (adults) or 10- 20 mg
/kg/day( children < 15 years ) PO or IV
Rasburicase 0.1-0.2 mg /kg or fixed dose IV daily
May be proffered n pediatrics
Use loop diuretics as needed to administer aggressive
IV hydration
Cairo MS et al Br J Haematol 2010; 149:578-86
12. CASE NO: 01
RD is a 59 year old male with newly diagnosed Burkitt’s
Lymphoma. Labs reveals WBC 12*109/ L , LDH = 810 IU/L ,
Potassium =5.7 mEq/L , SrCr= 2.1 mg/dl and uric acid 8.6
mg/dL .Vital signs and EKG are normal. Along with
allopurinol, which of the following is best to order first ?
a. 0.9% NS 1000ml * 1wide open
b. Rasburicase 0.2 mg /kg Iv *1
c. Sodium polystyrene Sulfonate
d. Consult for emergent renal dialysis
13. PRINCIPLES OF TLS TREATMENT
GOAL: maximize renal excretion of electrolytes
Treat each metabolic derangement
Backbone of TLS treatment
Saline –containing IVF to maintain urine output of
greater than equal to 100 ml/ hr
Allopurinol 300-900 mg daily in divided doses.
Will A. Tholour E. Br J Haematol 2011;154:3-13
Wetzstein GA Oncology Special Edition. 2004:7:125-8
15. CASE NO :02
MM is a 62 year old female who received first cycle
of paclitaxel / carboplatin 12 days ago. She comes
to your cancer center clinic with 101 ºF fever and
BP 81/60 She has severe Mucositis.She has PICC
Line. Lab revealWBC 500/mm 3 with 10 %
granulocytes. Which of the following is best at this
time?
a. Low risk febrile neutropenia (FN) treat with
ciprofloxacin + amoxicillin/clavulanate
b. Low risk FN: treat with cephalexin
c. High risk FN: treat with cefipime
d. High risk FN: treat with meropenem and
vancomycin
16. DEFINITIONS
o Neutropenia:
Absolute ANC < 0.5*109/L
<1*109 /L with a predicted decreased to < 0.5 *109
/L in next 48 hours.
FEBRILE NEUTOPENIA:
ANC < 0.5 *109 /L & a single PO temp > 101 ºF
(38.3º C) or > 100.4 ºF(38 ºC) for at least an hour.
Usual signs / symptoms of infection absent; fever
only reliable indicator
Freifeld AG et al Clin Infect Dis. 2011;52 e56-93.
17. FEBRILE NEUTROPENIAAND WBC
COLONY -STIMULATING FACTOR
PRIMARY PROPHYLAXIS
Expect greater than equal to 20% incidence of FN.
SECONDARY PROPHYLAXIS
Experienced prior neutropenic complications and dose reduction
may compromise survival.
o Do not use WBC CSF for the treatment of
established FN
Smith T J et al J Clin Oncol. 2006;24:3187-205
Freifeld AG et al Clin Infect Dis 2011:52e56-93
18. PREVENTION OF FEBRILE NEUTROPENIA
NCCN & IDSA GUIDELINES :
Consider fluoroquinolones in high risk
Expected ANC < 1*10 9 /L > 7 days
Levofloxacin & ciprofloxacin have most data & are
considered roughly equivalent
Role of anti bacterial prophylaxis controversial
No data showing improvement in over all survival or reduction
in incidence / severity of FN
Freifeld AG et al Clin Infect Dis 2011:52e56-93
NCCN Clinical Practice guidelines-prevention & treatment of Cancer Related Infections ver1-2016
19. PREVENTION OF FEBRILE NEUTROPENIA
Antibacterial prophylaxis not recommended for
low risk patients.
< 7 days neutropenia
2009 ASCO guidelines : amifostine may reduce
grade 3 and 4 neutropenia associated with
chemotherapy:
However dose reduction or use of CSF are alternatives
Freifeld AG et al Clin Infect Dis 2011:52e56-93
Hensley ML et al J Clin Oncol 2009;27:127-45
20. TREATMENT OF HIGH RISK FN
MASCC SCORE < 21
Patient with any of the following condition
Hospitalized at onset of fevers
Clinically unstable (hypotension)
Significant co-morbidities ( pneumonia )
Prolonged , severe neutropenia
ANC less than equal to 0.1*10 9 /L for > 7 days
Abnormal liver or renal function
Grade 3 or 4 mucositis or enteritis
Uncontrolled cancer
Freifeld AG et al Clin Infect Dis 2011:52e56-93
Freifeld AG et al Clin Infect Dis 2011:52e56-93
NCCN Clinical Practice guidelines-prevention & treatment of Cancer Related Infections ver1-2016
21. MASCC SCORING INDEX
CHARACTERISTICS SCORE
Absent to mild symptoms
Moderate symptoms
Severe
5
3
0
No hypotension (SBP > 90 mm Hg) 5
No COPD (presently or past medical
history)
4
Solid tumor or lymphoma w/o fungal
infection
4
No dehydration 3
Outptaient status ( at onset of fever) 3
Age < 60 years 2
Score greater than equal to 21 (out of 26 possible ) = low risk
Klastersky J et al Supportive Care Cancer 2013;21:1487-95
22. EMPIRIC TREATMENT FOR LOW RISK –FN
Preferred therapy : ciprofloxacin +
amoxicillin/clavulanate
If penicillin allergic: ciprofloacin + clindamycin
Attempt to maintain outpatient status
Avoid oral antibacterials in patients who received
fluoroquinolones prophylaxis
Flowers CR et al J Clin Oncol.2013;31:794-810
23. EMPIRIC TREATMENT OF HIGH RISK –FN
Requires IV Antibiotics & inpatient status
Cefepime
Ceftazidime
Note: resistance increasing to ceftazidime
Antipseudomonal carbapenem ( imipenem –cilastatin , or
meropenem)
Piperacillin /tazobactum
Note: doses for FN indications different than non-FN
indications
Freifeld AG et al Clin Infect Dis 2011:52e56-93
NCCN Clinical Practice guidelines-prevention & treatment of Cancer Related Infections ver1-2016
24. TREATMENT PRINCIPLES FOR FN-
COMBINATION THERAPY
Six indications to add gram positive agent
1. Sepsis syndrome / hemodynamic instability
2. Skin or skin structure infections (SSSI)
3. Central catheter- related infection
4. Colonization with MRSA , penicillin resistant s.pneumonia
or vancomycin- resistant enterococci spp.
5. Gram positive organism cultured
6. Severe mucositis
Freifeld AG et al Clin Infect Dis 2011:52e56-93
NCCN Clinical Practice guidelines-prevention & treatment of Cancer Related Infections ver1-2016
25. CASE NO :02
MM is a 62 year old female who received first cycle
of paclitaxel / carboplatin 12 days ago. She comes
to your cancer center clinic with 101 ºF fever and
BP 81/60 She has severe Mucositis.She has PICC
Line. Lab revealWBC 500/mm 3 with 10 %
granulocytes. Which of the following is best at this
time?
a. Low risk febrile neutropenia (FN) treat with
ciprofloxacin + amoxicillin/clavulanate
b. Low risk FN: treat with cephalexin
c. High risk FN: treat with cefipime
d. High risk FN: treat with meropenem and
vancomycin
26. WHEN TO MODIFY EMPIRIC TREATMENT
CLINICAL SCENARIO ACTION TO TAKE
Antimirobial resistance ( actual or
suspected )
Add aminoglycosides,colistin,
fluoroquinolones and/or
vancomycin
Pneumonia Add vancomycin or linezolid , Add
aminoglycsides , switch to
carbapenems .
Cellulitis Add vancomycin or linezolid
Abdominal symptoms switch to carbapenems or
piperacillin/ tazobactum , add
metronidazole or oral vancomycin (
if suspect c.difficile)
27. WHEN TO MODIFY EMPIRIC
TREATMENT
CLINICAL SCENARIO ACTIONS TO TAKE
MRSA (BLOOD ) Add Vancomycin , Linezolid Or
Daptomycin
MRSA (Pneumonia) Add Vancomycin or Linezolid , add
aminoglycosides.
Extended spectrum beta-
lactamase ( ESBL )gram negative
bacteria
Switch to anti –pseudomonal
carbapenems
Klebsiella pneumonia
carbapenamase (KPC) positive
gram negative bacteria
Add colistin or tigecycline
28. TREATMENT PRINCIPLES FOR FN
(CONT.)
Once daily and standard dosing of aminglycosides
are acceptable
Avoid synergy dosing
Consider linezolid or daptomycin for MRSA with
vancomycin MIC greater than equal to 2ug/ml
Avoid daptomycin altogether for pneumonia
Freifeld AG et al Clin Infect Dis 2011:52e56-93
NCCN Clinical Practice guidelines-prevention & treatment of Cancer Related Infections ver1-2016
29. TREAT FN IN CLINICALLY UNSTABLE
PATIENT
INDICATIONS : Sepsis syndrome , mental status
changes, tachypnea,etc
EMPIRIC THERAPY WITH:
Carbapenem or piperacillin /tazobactam plus
Aminoglycoside plus
Gram positive agent (vancomycin if pneumonia)
+/-
Fluconazole or echinocandin
NCCN Clinical Practice guidelines-prevention & treatment of Cancer Related Infections ver1-2016
30. TREATMENT DURATION – ORGANISM
CULTURED
Continue therapy until ANC > 0.5*10 9 /L
Uncomplicated bacteremia = 10-14 D
Uncomplicated GI or skin & skin structure
infection = 7-14 d
Complicated bacteremia , pneumonia & upper
respiratory infections =10-21 D
Typhlitis = treat until all evidence of infection
resolved & neutropenia resolved.
NCCN Clinical Practice guidelines-prevention & treatment of Cancer Related Infections ver1-2016
31. RECALCITRANT FN DESPITE BROAD
SPECTRUM ANTI BACTERIALS
Consider drug induced fever
Add empiric antifungal:
After 4-7 days of broad spectrum antibacterials
And
Anticipated neutropenia duration > 7 d
And
No fever source identified
Patel RA.Gallagher JC Pharmacothera.2010;30:57-59
Freifeld AG et al Clin Infect Dis 2011:52e56-93
NCCN Clinical Practice guidelines-prevention & treatment of Cancer Related Infections ver1-2016
32. TREATMENT OF CENTRAL VENOUS
CATHETER INFECTION
Remove catheter if culture positive for
S.aureus
P.aeroginosa
Fungi
Mycobacteria
Retain catheter if coagulase-negative
staphylococcus infection
Treat with systemic +/- antibiotic lock
Freifeld AG et al Clin Infect Dis 2011:52e56-93
Mermel LA et al Clin infect Dis. 2009.49:1-45
33. FOLLOW – UP OF FN PATIENT
If vancomycin added empirically and no evidence
of gram positive infection, discontinue after 2-3
days
For low risk FN patients receiving IV
antibacterial, may changed to oral if GI absorption
adequate
No IV to PO switch recommendation for high risk –FN
Freifeld AG et al Clin Infect Dis 2011:52e56-93